Inverse Microlatex Vaccine Adjuvant Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Formulating a ready-to-use polymeric oily vaccine adjuvant that is stable, easily sterilizable, and capable of forming stable emulsions over time is challenging due to issues with polymer stabilization, phase separation, and compatibility with sterilization methods, which complicates the production of effective and long-lasting vaccine compositions.
Innovation Solution
A vaccine adjuvant comprising an inverse microlatex with an anionic and crosslinked polyelectrolyte-type polymer, prepared through a process involving radical polymerization and homogenization, which includes an oily phase, aqueous phase, and specific surfactants to create a stable and sterilizable formulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a polymeric oily vaccine adjuvant is formulated to be stable and sterilizable, then reliability and ease of manufacture are improved, but device complexity and manufacturing precision deteriorate due to polymer stabilization and phase separation issues
Solution Approach 1:
The patent uses a composite system consisting of an inverse microlatex (polymer phase) dispersed in an oily adjuvant matrix. This composite structure allows the polymeric components to provide immunostimulatory stability while the oily matrix provides ease of sterilization and handling, resolving the contradiction between reliability and device complexity
Solution Approach 2:
The inverse microlatex acts as an intermediary carrier that stabilizes the polymeric adjuvant components within the oily matrix. This intermediary structure prevents direct phase separation and polymer aggregation, enabling both stability and manufacturability without excessive complexity
2Ease of operation
If the adjuvant is made ready-to-use with direct emulsification capability, then ease of operation is improved, but manufacturing precision deteriorates due to phase separation issues
Solution Approach 1:
The adjuvant is pre-formulated as a ready-to-use composition with all necessary components (inverse microlatex, oily matrix, surfactants) properly integrated before use. This preliminary preparation ensures that when the adjuvant is mixed with aqueous antigen, homogeneous emulsion forms immediately without requiring additional manufacturing steps, thus improving ease of operation while maintaining manufacturing precision
3Reliability
If multiple production steps are used to ensure stability, then reliability is improved, but productivity deteriorates due to energy consumption and time requirements
Solution Approach 1:
The patent merges multiple functions into a single integrated formulation: the inverse microlatex provides both polymer stabilization and emulsification capability, while the oily matrix simultaneously provides sterilization compatibility and long-term stability. This merging eliminates the need for separate production steps, improving productivity while maintaining reliability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution provides a stable polymeric oily adjuvant that remains effective for over a year at various temperatures, facilitating the production of long-lasting and immunologically effective vaccine compositions that can be easily sterilized and used directly with antigens, reducing the need for multiple steps and energy consumption.
Implementation Method 1
an inverse microlatex denotes an inverse microemulsion comprising at least one polyelectrolyte-type polymer
Implementation Method 2
prepared through a process involving radical polymerization and homogenization
Data Source
AI summary
Disclosed is a vaccine adjuvant including at least one inverse microlatex, the inverse microlatex including at least one oil, at least one surfactant, at least one polymer such as, for example, a polyacrylate that is totally or partially neutralized in the form of alkali metal salts or ammonium salt, the vaccine adjuvant being entirely sterilizable by filtration or by passing through the heat of an autoclave and emulsifiable in one step with the aqueous phase including only a vaccine antigen.